Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $28000.0.

  • Corvus Pharmaceuticals' Depreciation & Amortization (CF) rose 3333.33% to $28000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $99000.0, marking a year-over-year increase of 645.16%. This contributed to the annual value of $85000.0 for FY2024, which is 4370.86% down from last year.
  • Corvus Pharmaceuticals' Depreciation & Amortization (CF) amounted to $28000.0 in Q3 2025, which was up 3333.33% from $29000.0 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $94000.0 during Q3 2022, with a 5-year trough of $20000.0 in Q4 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' median Depreciation & Amortization (CF) value was $29000.0 (recorded in 2025), while the average stood at $45466.7.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Depreciation & Amortization (CF) tumbled by 7021.28% in 2023, and later soared by 3809.52% in 2025.
  • Corvus Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $94000.0 in 2022, then crashed by 70.21% to $28000.0 in 2023, then fell by 28.57% to $20000.0 in 2024, then surged by 40.0% to $28000.0 in 2025.
  • Its last three reported values are $28000.0 in Q3 2025, $29000.0 for Q2 2025, and $22000.0 during Q1 2025.